New lupus treatment enters human testing

NCT ID NCT06625671

Recruiting now Disease control Sponsor: DualityBio Inc. Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new drug called DB-2304 to see if it is safe and how the body handles it. It will involve both healthy adults and people with systemic or skin lupus. The main goal is to check for side effects and measure how the drug behaves in the body before testing if it helps control lupus symptoms.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site AUS01-0
COMPLETED

Melbourne, Victoria, 3004, Australia
US02-0
RECRUITING

San Antonio, Texas, 78215, United States
US03-0
RECRUITING

Clearwater, Florida, 33765, United States
US04-0
RECRUITING

Irving, Texas, 75061, United States

Conditions

Explore the condition pages connected to this study.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)